🧬Congratulations to portfolio company Mission Therapeutics, which has raised $13.3 million to progress first-in-class Parkinson’s disease candidate MTX325 through clinical trials. We’re proud to have supported this round and to continue backing Mission’s ground-breaking work. 👇 Link to full release in comments
IP Group plc’s Post
Explore content categories
- Career
- Productivity
- Finance
- Soft Skills & Emotional Intelligence
- Project Management
- Education
- Technology
- Leadership
- Ecommerce
- User Experience
- Recruitment & HR
- Customer Experience
- Real Estate
- Marketing
- Sales
- Retail & Merchandising
- Science
- Supply Chain Management
- Future Of Work
- Consulting
- Writing
- Economics
- Artificial Intelligence
- Employee Experience
- Workplace Trends
- Fundraising
- Networking
- Corporate Social Responsibility
- Negotiation
- Communication
- Engineering
- Hospitality & Tourism
- Business Strategy
- Change Management
- Organizational Culture
- Design
- Innovation
- Event Planning
- Training & Development
https://www.ipgroupplc.com/news-and-events/portfolio-news/2025/2025-10-15